10 products found
Starpharma Holdings Limited Products
-
Starpharma - Dendrimer Platform Technology
Starpharma’s technology is based on a type of polymer, a highly branched, roughly spherical polymer – called a dendrimer. Dendrimers are precise, synthetically manufactured, nanoscale molecules with unique properties that make them useful to the health and pharmaceutical industry to enhance existing products and as entirely new products. Starpharma's dendrimer technology allows the creation of specifically defined nanoparticles that are ...
-
VIRALEZE - Antiviral Nasal Spray
VIRALEZE™ is an antiviral nasal spray that contains astodrimer sodium (SPL7013), which has been shown in laboratory studies to inactivate a broad spectrum of respiratory viruses, including >99.9% of coronavirus SARS-CoV-2, the virus that causes ...
-
VivaGel
-
Starpharma VivaGel - Innovative Technology
VivaGel® (SPL7013, or astodrimer sodium) is an innovative agent applied to a range of marketed women’s health and sexual wellness products. The safety and efficacy of VivaGel® has been successfully tested in several clinical studies. VivaGel® is a proprietary dendrimer that is antiviral and blocks bacteria. When formulated as a mucoadhesive gel and delivered vaginally, ...
-
VivaGel - Model BV - Gel for Bacterial Vaginosis
VivaGel® BV is available for sale under the brand names Betafem® BV Gel (UK), Betadine BVTM (Europe), BetadineTM BV Gel (Asia) and Fleurstat BVgel (Australia & New Zealand). VivaGel® has been developed for the treatment of BV and prevention of recurrent bacterial vaginosis (BV). BV is caused by an imbalance of the normal vaginal bacterial ...
-
VivaGel® - Condom
Starpharma’s VivaGel® condom is the world’s first and only antiviral condom. The physical barrier of the condom provides primary protection against sexually transmitted infections (STIs). The condom is lubricated with VivaGel® lubricant. VivaGel® (SPL7013, or astodrimer sodium) is an antiviral agent proven, in laboratory studies only, to inactivate HIV, herpes simplex virus (HSV) and human papillomavirus (HPV), which are ...
-
DEP® Drug Delivery
Starpharma’s dendrimers can be used to enhance the properties of other drugs. The approach is known as “drug delivery” because it is about working to ensure that the drug is delivered to the right part of the body at the right time. Starpharma`s dendrimer drug delivery technology is known as DEP®. Starpharma uses DEP® both in its own drug development pipeline and with partners. The most advanced DEP® product in Starpharma`s pipeline is DEP® docetaxel which is in Phase 2 clinical trials.
-
Starpharma DEP - Docetaxel
DEP® docetaxel is an enhanced version of docetaxel (Taxotere®) – widely used for breast, lung & prostate cancer. Docetaxel (Taxotere®) is a commonly used chemotherapy agent despite having multiple US FDA “Black Box” warnings. DEP® docetaxel is a detergent free, aqueous formulation of ...Starpharma - Prostate Cancer Drug Cabazitaxel
DEP® cabazitaxel is an enhanced version of leading prostate cancer drug cabazitaxel (Jevtana®). Cabazitaxel (Jevtana®) had global sales of €536M in 2020 despite having multiple US FDA “Black Box” ...
Starpharma - DEP® irinotecan (Phase 2)
DEP® irinotecan is an improved version of irinotecan (Camptosar®), predominantly used for colorectal cancer. DEP® irinotecan is a novel, patented nanoparticle formulation of SN-38, the active metabolite of irinotecan, delivered using Starpharma’s proprietary DEP® technology. Irinotecan (Camptosar®) is a major cancer drug used to treat colorectal cancer with peak global sales of >US$1.1 billion despite having multiple US FDA ...
Starpharma - Antibody Drug Conjugates
Starpharma’s DEP® technology provides enhanced therapeutic benefits to Antibody Drug Conjugates (ADCs) including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches. The use of ADCs is an innovative and cutting-edge area in cancer therapy that continues to grow, and Starpharma has a number of partner programs in the area. Starpharma’s novel ...
Starpharma - DEP® Radiotheranostics
DEP® radiotheranostic conjugates have the potential to minimise off-target toxicity, optimise pharmacokinetics and enhance efficacy when used alone or in combination with other therapeutic approaches. The versatility of Starpharma’s DEP® platform means it can be used with a wide range of therapies and types of molecules (e.g., small molecule drugs, peptides, antibodies, radioisotopes). This flexibility has allowed Starpharma to develop a ...